









Markets
/
Stocks
/
nasdaq-cmmb
/

Chemomab Therapeutics Ltd

CMMB

2.650USD

+0.020+0.76%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

54.84MMarket Cap

LossP/E TTM



Chemomab Therapeutics Ltd

2.650

+0.020+0.76%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

222 / 506

Overall Ranking

357 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

29.667

Target Price

+1028.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Undervalued

The company’s latest PE is -5.47, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.04M shares, decreasing 15.56% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -5.42, which is -65.13% below the recent high of -1.89 and 55.89% above the recent low of -2.39.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 222/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Chemomab Therapeutics Ltd is 28.00, with a high of 36.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

29.667

Target Price

+1028.01%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Chemomab Therapeutics Ltd

CMMB

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.03, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 4.05 and the support level at 1.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.03

Change

0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.206

Neutral

RSI(14)

58.256

Neutral

STOCH(KDJ)(9,3,3)

12.019

Oversold

ATR(14)

0.159

Low Volatility

CCI(14)

-129.688

Sell

Williams %R

88.976

Oversold

TRIX(12,20)

2.885

Buy

StochRSI(14)

10.970

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.704

Sell

MA10

2.869

Sell

MA20

2.807

Sell

MA50

1.742

Buy

MA100

1.505

Buy

MA200

1.567

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Otto (Erik)

1.16M

Morgan Stanley & Co. LLC

117.16K

+12.22%

Apeiron Investment Group Ltd

1.13M

+55.68%

Rivendell Investments 2017-9 LLC

1.11M

OrbiMed Advisors, LLC

131.27K

-92.46%

Sphera Funds Management Ltd.

900.43K

-25.86%

Yelin Lapidot Provident Funds Management Ltd

578.29K

-22.29%

Mor George (Adi)

317.07K

Ikarian Capital LLC

213.05K

George (Kobi)

200.24K

-20.27%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.13, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.58. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.